文献速递心境障碍精神分裂症与精神病性障碍

精神病理与认知中的循环血液蛋白:一项孟德尔随机化研究

Circulating Blood-Based Proteins in Psychopathology and Cognition: A Mendelian Randomization Study.
PubMed 文献 · JAMA Psychiatry · 2025-01-01

该研究采用两样本孟德尔随机化设计,利用UK Biobank Pharma Proteomics Project(2923种蛋白/34557人)和deCODE Genetics(4719种蛋白/35559人)的血浆蛋白组数据构建工具变量,评估循环蛋白对精神分裂症、双相障碍、重性抑郁障碍及认知任务表现的潜在因果效应,共发现113个Bonferroni校正显著关联(46个为新发现),涉及91种蛋白,并提示抗炎药、金刚烷胺、维A酸、度洛西汀等药物重定位可能。

要点

  • 113个Bonferroni校正显著关联涉及91种蛋白,其中46个为新发现。
  • 白介素、补体因子等免疫相关蛋白在多个结局表型间显示多效性。
  • 药物靶点富集分析支持抗炎药用于精神分裂症、金刚烷胺用于双相障碍、维A酸用于重性抑郁障碍、度洛西汀用于认知任务表现的重定位。

核心结论

  • 识别循环蛋白对神经精神表型的潜在因果效应,提示潜在生物标志物并为创新治疗策略开发提供线索。
  • 许多蛋白在不同表型间显示多效性,提示严重精神疾病与认知之间存在共享病因。

研究设计与样本

  • 两样本孟德尔随机化设计,以显著蛋白组定量性状位点作为候选工具变量。
  • 工具变量来自UK Biobank Pharma Proteomics Project(每位34557名英国个体2923种蛋白)和deCODE Genetics(每位35559名冰岛个体4719种蛋白)两个大规模血浆蛋白组数据集。
  • 数据分析于2023年11月至2024年11月进行。

主要发现

  • 孟德尔随机化分析在4个结局表型中共发现113个Bonferroni校正关联(46个为新发现),涉及91种蛋白。
  • 白介素和补体因子等免疫相关蛋白在多个结局表型间显示多效性效应。
  • 药物靶点富集分析支持抗炎药用于精神分裂症、金刚烷胺用于双相障碍、维A酸用于重性抑郁障碍、度洛西汀用于认知任务表现的重定位。

关键数值与推荐

  • 结局数据来自近期大规模全基因组关联研究的汇总统计:精神分裂症(67323例病例和93456例对照)、双相障碍(40463例病例和313436例对照)、重性抑郁障碍(166773例病例和507679例对照)、认知任务表现(215333名个体)。
  • 孟德尔随机化分析中Bonferroni校正P < .05的关联被视为统计学显著。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Peripheral (blood-based) biomarkers for psychiatric illness could benefit diagnosis and treatment, but research to date has typically been low throughput, and traditional case-control studies are subject to potential confounds of treatment and other exposures. Large-scale 2-sample mendelian randomization (MR) can examine the potentially causal impact of circulating proteins on neuropsychiatric phenotypes without these confounds. OBJECTIVE: To identify circulating proteins associated with risk for schizophrenia (SCZ), bipolar disorder (BD), and major depressive disorder (MDD) as well as cognitive task performance (CTP). DESIGN, SETTING, AND PARTICIPANTS: In a 2-sample MR design, significant proteomic quantitative trait loci were used as candidate instruments, obtained from 2 large-scale plasma proteomics datasets: the UK Biobank Pharma Proteomics Project (2923 proteins per 34 557 UK individuals) and deCODE Genetics (4719 proteins per 35 559 Icelandic individuals). Data analysis was performed from November 2023 to November 2024. EXPOSURE: Genetic influence on circulating levels of proteins in plasma. MAIN OUTCOMES AND MEASURES: Outcome measures were summary statistics drawn from recent large-scale genome-wide association studies for SCZ (67 323 cases and 93 456 controls), BD (40 463 cases and 313 436 controls), MDD (166 773 cases and 507 679 controls), and CTP (215 333 individuals). MR was carried out for each phenotype, and proteins that showed statistically significant (Bonferroni-corrected P < .05) associations from MR analysis were used for pathway, protein-protein interaction, drug target enrichment, and potential druggability analysis for each outcome phenotype separately. RESULTS: MR analysis revealed 113 Bonferroni-corrected associations (46 novel) involving 91 proteins across the 4 outcome phenotypes. Immune-related proteins, such as interleukins and complement factors, showed pleiotropic effects across multiple outcome phenotypes. Drug target enrichment analysis provided support for repurposing of anti-inflammatory agents for SCZ, amantadine for BD, retinoic acid for MDD, and duloxetine for CTP. CONCLUSIONS AND RELEVANCE: Identifying potentially causal effects of circulating proteins on neuropsychiatric phenotypes suggests potential biomarkers and offers insights for the development of innovative therapeutic strategies. The study also reveals pleiotropic effects of many proteins across different phenotypes, indicating shared etiology among serious psychiatric conditions and cognition.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Bhattacharyya U, John J, Lam M, et al. Circulating Blood-Based Proteins in Psychopathology and Cognition: A Mendelian Randomization Study. JAMA Psychiatry. 2025. PMID: 40072421. doi:10.1001/jamapsychiatry.2025.0033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。